Paraoxonase and Atherosclerosis
By P. Durrington, B. Mackness, M. Mackness. Arteriosclerosis, Thrombosis and Vascular Biology, 2001
855 citations recorded by the source corpus.
Subfields: Biochemistry, Clinical Biochemistry, Plant Science
View Paper: https://www.semanticscholar.org/paper/dca9f75e006877c8fa8dbdb13fb0953218804968
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- P. Barter
- S. Nicholls
- A. Fogelman
- M. Navab
- K. Rye
- G. Anantharamaiah
- Y. Osawa
- A. Speelman
Citations in the corpus
- Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M (2005, background): “HDL’s ability to prevent oxidative modifications of LDL has been attributed to PON1 (19–22), and serum PON1 levels are inversely proportional to the risk of coronary heart disease (23, 24).”
- Antiinflammatory Properties of HDL (2004, background): “However, HDL particles also carry enzymes that retard LDL oxidation, including paraoxonase (PON), platelet-activating factor acetylhydrolase (PAFAH), and lecithin-cholesterol acyltransferase (LCAT) [4,34].”